M&A / Deals Eli Lilly makes $7.8bn takeover play for Centessa PharmaphorumSleep disorder specialist Centessa is heading for an acquisition by Eli Lilly, which has offered $6.3bn for the US and UK-based biotech.M&A / DealsRead full story pharminent March 31, 2026 (Last updated: March 31, 2026) Pharmaphorum Sleep disorder specialist Centessa is heading for an acquisition by Eli Lilly, which has offered $6.3bn for the US and UK-based biotech. M&A / DealsRead full story Post navigation Previous: Merck strikes deal with antibody discovery startupNext: Biogen swoops on Apellis with $5.6bn offer Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026